{"doc_id": "33069281", "type of study": "Therapy", "title": "", "abstract": "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.\nThe ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates.\nWe aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans.\nWe did a randomised, double-blind, placebo-controlled, phase 1/2 trial at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan Province, China.\nIn phase 1, healthy people aged 18-80 years, who were negative for serum-specific IgM/IgG antibodies against SARS-CoV-2 at the time of screening, were separated into two age groups (18-59 years and \u226560 years) and randomly assigned to receive vaccine or placebo in a two-dose schedule of 2 \u03bcg, 4 \u03bcg, or 8 \u03bcg on days 0 and 28.\nIn phase 2, healthy adults (aged 18-59 years) were randomly assigned (1:1:1:1) to receive vaccine or placebo on a single-dose schedule of 8 \u03bcg on day 0 or on a two-dose schedule of 4 \u03bcg on days 0 and 14, 0 and 21, or 0 and 28.\nParticipants within each cohort were randomly assigned by stratified block randomisation (block size eight) and allocated (3:1) to receive vaccine or placebo.\nGroup allocation was concealed from participants, investigators, and outcome assessors.\nThe primary outcomes were safety and tolerability.\nThe secondary outcome was immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2.\nThis study is registered with www.chictr.org.cn, ChiCTR2000032459.\nIn phase 1, 192 participants were enrolled (mean age 53\u00b77 years [SD 15\u00b76]) and were randomly assigned to receive vaccine (2 \u03bcg [n=24], 4 \u03bcg [n=24], or 8 \u03bcg [n=24] for both age groups [18-59 years and \u226560 years]) or placebo (n=24).\nAt least one adverse reaction was reported within the first 7 days of inoculation in 42 (29%) of 144 vaccine recipients.\nThe most common systematic adverse reaction was fever (18-59 years, one [4%] in the 2 \u03bcg group, one [4%] in the 4 \u03bcg group, and two [8%] in the 8 \u03bcg group; \u226560 years, one [4%] in the 8 \u03bcg group).\nAll adverse reactions were mild or moderate in severity.\nNo serious adverse event was reported within 28 days post vaccination.\nNeutralising antibody geometric mean titres were higher at day 42 in the group aged 18-59 years (87\u00b77 [95% CI 64\u00b79-118\u00b76], 2 \u03bcg group; 211\u00b72 [158\u00b79-280\u00b76], 4 \u03bcg group; and 228\u00b77 [186\u00b71-281\u00b71], 8 \u03bcg group) and the group aged 60 years and older (80\u00b77 [65\u00b74-99\u00b76], 2 \u03bcg group; 131\u00b75 [108\u00b72-159\u00b77], 4 \u03bcg group; and 170\u00b787 [133\u00b70-219\u00b75], 8 \u03bcg group) compared with the placebo group (2\u00b70 [2\u00b70-2\u00b70]).\nIn phase 2, 448 participants were enrolled (mean age 41\u00b77 years [SD 9\u00b79]) and were randomly assigned to receive the vaccine (8 \u03bcg on day 0 [n=84] or 4 \u03bcg on days 0 and 14 [n=84], days 0 and 21 [n=84], or days 0 and 28 [n=84]) or placebo on the same schedules (n=112).\nAt least one adverse reaction within the first 7 days was reported in 76 (23%) of 336 vaccine recipients (33 [39%], 8 \u03bcg day 0; 18 [21%], 4 \u03bcg days 0 and 14; 15 [18%], 4 \u03bcg days 0 and 21; and ten [12%], 4 \u03bcg days 0 and 28).\nOne placebo recipient in the 4 \u03bcg days 0 and 21 group reported grade 3 fever, but was self-limited and recovered.\nAll other adverse reactions were mild or moderate in severity.\nThe most common systematic adverse reaction was fever (one [1%], 8 \u03bcg day 0; one [1%], 4 \u03bcg days 0 and 14; three [4%], 4 \u03bcg days 0 and 21; two [2%], 4 \u03bcg days 0 and 28).\nThe vaccine-elicited neutralising antibody titres on day 28 were significantly greater in the 4 \u03bcg days 0 and 14 (169\u00b75, 95% CI 132\u00b72-217\u00b71), days 0 and 21 (282\u00b77, 221\u00b72-361\u00b74), and days 0 and 28 (218\u00b70, 181\u00b78-261\u00b73) schedules than the 8 \u03bcg day 0 schedule (14\u00b77, 11\u00b76-18\u00b78; all p<0\u00b7001).\nThe inactivated SARS-CoV-2 vaccine, BBIBP-CorV, is safe and well tolerated at all tested doses in two age groups.\nHumoral responses against SARS-CoV-2 were induced in all vaccine recipients on day 42.\nTwo-dose immunisation with 4 \u03bcg vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres than the single 8 \u03bcg dose or 4 \u03bcg dose on days 0 and 14.\nNational Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 20}, {"term": "serum-specific", "negation": "negated", "UMLS": {}, "start": 69, "end": 83}, {"term": "IgG antibodies against SARS-CoV-2", "negation": "negated", "UMLS": {}, "start": 90, "end": 123}, {"term": "healthy adults", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 27}, {"term": "18-59 years", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 95}, {"term": "aged 60 years and older", "negation": "affirmed", "UMLS": {}, "start": 233, "end": 256}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine , BBIBP-CorV : a randomised , double-blind , placebo-controlled , phase 1 / 2 trial .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 62, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "BBIBP-CorV", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 75, "has_relation": "N/A"}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 25}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) vaccine candidate , BBIBP-CorV , in humans .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) vaccine", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 137, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 60, "end": 67, "has_count": ["2"]}], "has_procedure": [{"text": "inactivated severe acute respiratory syndrome coronavirus", "maps_to": "C5401375:Coronavirus", "start": 0, "end": 57}], "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 29}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 48}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We did a randomised , double-blind , placebo-controlled , phase 1 / 2 trial at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan Province , China .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In phase 1 , healthy people aged 18-80 years , who were negative for serum-specific IgM / IgG antibodies against SARS-CoV-2 at the time of screening , were separated into two age groups ( 18-59 years and \u226560 years ) and randomly assigned to receive vaccine or placebo in a two-dose schedule of 2 \u03bcg , 4 \u03bcg , or 8 \u03bcg on days 0 and 28 .", "Evidence Elements": {"Participant": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 20}, {"term": "serum-specific", "negation": "negated", "UMLS": {}, "start": 69, "end": 83}, {"term": "IgG antibodies against SARS-CoV-2", "negation": "negated", "UMLS": {}, "start": 90, "end": 123}], "Intervention": [{"term": "vaccine", "negation": "negated", "UMLS": {}, "start": 249, "end": 256, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 260, "end": 267, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In phase 2 , healthy adults ( aged 18-59 years ) were randomly assigned ( 1:1:1:1 ) to receive vaccine or placebo on a single-dose schedule of 8 \u03bcg on day 0 or on a two-dose schedule of 4 \u03bcg on days 0 and 14 , 0 and 21 , or 0 and 28 .", "Evidence Elements": {"Participant": [{"term": "healthy adults", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 27}], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 102, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 113, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants within each cohort were randomly assigned by stratified block randomisation ( block size eight ) and allocated ( 3:1) to receive vaccine or placebo .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Group allocation was concealed from participants , investigators , and outcome assessors .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcomes were safety and tolerability .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 32}, {"term": "tolerability", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 49}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The secondary outcome was immunogenicity , assessed as the neutralising antibody responses against infectious SARS-CoV-2 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 40}, {"term": "neutralising antibody responses against infectious", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 109}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study is registered with www . chictr.org.cn , ChiCTR2000032459 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "In phase 1 , 192 participants were enrolled ( mean age 53\u00b77 years [ SD 15\u00b76 ] ) and were randomly assigned to receive vaccine ( 2 \u03bcg [ n = 24 ] , 4 \u03bcg [ n = 24 ] , or 8 \u03bcg [ n = 24 ] for both age groups [ 18-59 years and \u226560 years ] ) or placebo ( n = 24 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 125, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "At least one adverse reaction was reported within the first 7 days of inoculation in 42 ( 29 % ) of 144 vaccine recipients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "At least one adverse reaction", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 29}], "Observation": [], "Count": [{"term": "42 ( 29 % ) of", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 99}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The most common systematic adverse reaction was fever ( 18-59 years , one [ 4 % ] in the 2 \u03bcg group , one [ 4 % ] in the 4 \u03bcg group , and two [ 8 % ] in the 8 \u03bcg group ; \u226560 years , one [ 4 % ] in the 8 \u03bcg group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "2 \u03bcg", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 93, "has_relation": "N/A"}, {"term": "4 \u03bcg", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 125, "has_relation": "N/A"}], "Outcome": [{"term": "fever", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 53}], "Observation": [{"term": "most common", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}], "Count": [{"term": "one [ 4 % ]", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 81}, {"term": "one [ 4 % ]", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 81}, {"term": "two [ 8 % ]", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 149}]}, "Evidence Propositions": [{"Intervention": [], "Observation": "most common", "Outcome": "fever", "Count": ""}, {"Intervention": {"term": "2 \u03bcg", "has_relation": "N/A"}, "Observation": "", "Count": "one [ 4 % ]", "Outcome": "fever"}, {"Intervention": {"term": "4 \u03bcg", "has_relation": "N/A"}, "Observation": "", "Count": "one [ 4 % ]", "Outcome": "fever"}]}, {"Section": "FINDINGS", "Text": "All adverse reactions were mild or moderate in severity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "All adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21}], "Observation": [{"term": "mild or moderate", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 43}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "No serious adverse event was reported within 28 days post vaccination .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse event", "negation": "negated", "UMLS": {}, "start": 3, "end": 24}], "Observation": [], "Count": [{"term": "No", "negation": "negated", "UMLS": {}, "start": 0, "end": 2}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Neutralising antibody geometric mean titres were higher at day 42 in the group aged 18-59 years ( 87\u00b77 [ 95 % CI 64\u00b79-118\u00b76 ] , 2 \u03bcg group ; 211\u00b72 [ 158\u00b79-280\u00b76 ] , 4 \u03bcg group ; and 228\u00b77 [ 186\u00b71-281\u00b71 ] , 8 \u03bcg group ) and the group aged 60 years and older ( 80\u00b77 [ 65\u00b74-99\u00b76 ] , 2 \u03bcg group ; 131\u00b75 [ 108\u00b72-159\u00b77 ] , 4 \u03bcg group ; and 170\u00b787 [ 133\u00b70-219\u00b75 ] , 8 \u03bcg group ) compared with the placebo group ( 2\u00b70 [ 2\u00b70-2\u00b70 ] ) .", "Evidence Elements": {"Participant": [{"term": "18-59 years", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 95}, {"term": "aged 60 years and older", "negation": "affirmed", "UMLS": {}, "start": 233, "end": 256}], "Intervention": [], "Outcome": [{"term": "Neutralising antibody geometric mean titres", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 43}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 55}, {"term": "211\u00b72", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 146}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "higher", "Outcome": "Neutralising antibody geometric mean titres", "Count": ""}]}, {"Section": "FINDINGS", "Text": "In phase 2 , 448 participants were enrolled ( mean age 41\u00b77 years [ SD 9\u00b79 ] ) and were randomly assigned to receive the vaccine ( 8 \u03bcg on day 0 [ n = 84 ] or 4 \u03bcg on days 0 and 14 [ n = 84 ] , days 0 and 21 [ n = 84 ] , or days 0 and 28 [ n = 84 ] ) or placebo on the same schedules ( n = 112 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 128, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "At least one adverse reaction within the first 7 days was reported in 76 ( 23 % ) of 336 vaccine recipients ( 33 [ 39 % ] , 8 \u03bcg day 0 ; 18 [ 21 % ] , 4 \u03bcg days 0 and 14 ; 15 [ 18 % ] , 4 \u03bcg days 0 and 21 ; and ten [ 12 % ] , 4 \u03bcg days 0 and 28 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine recipients", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 107, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "At least one adverse reaction", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 29}], "Observation": [], "Count": [{"term": "76 ( 23 % ) of 336", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 88}, {"term": "33 [ 39 % ]", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 121}, {"term": "18 [ 21 % ]", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 148}, {"term": "15 [ 18", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 179}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "One placebo recipient in the 4 \u03bcg days 0 and 21 group reported grade 3 fever , but was self-limited and recovered .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 11, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "grade 3 fever", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 76}, {"term": "self-limited", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 99}], "Observation": [], "Count": [{"term": "One", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "All other adverse reactions were mild or moderate in severity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "All other adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 27}], "Observation": [{"term": "mild or moderate", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 49}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The most common systematic adverse reaction was fever ( one [ 1 % ] , 8 \u03bcg day 0 ; one [ 1 % ] , 4 \u03bcg days 0 and 14 ; three [ 4 % ] , 4 \u03bcg days 0 and 21 ; two [ 2 % ] , 4 \u03bcg days 0 and 28 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "fever", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 53}], "Observation": [{"term": "most common", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}], "Count": [{"term": "one [ 1 % ]", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 67}, {"term": "one [ 1 % ]", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 67}, {"term": "three [ 4 % ]", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 131}]}, "Evidence Propositions": [{"Intervention": [], "Observation": "most common", "Outcome": "fever", "Count": ""}]}, {"Section": "FINDINGS", "Text": "The vaccine-elicited neutralising antibody titres on day 28 were significantly greater in the 4 \u03bcg days 0 and 14 ( 169\u00b75 , 95 % CI 132\u00b72-217\u00b71 ) , days 0 and 21 ( 282\u00b77 , 221\u00b72-361\u00b74 ) , and days 0 and 28 ( 218\u00b70 , 181\u00b78-261\u00b73 ) schedules than the 8 \u03bcg day 0 schedule ( 14\u00b77 , 11\u00b76-18\u00b78 ; all p < 0\u00b7001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "4 \u03bcg days 0 and 14", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 112, "has_relation": "N/A"}], "Outcome": [{"term": "vaccine-elicited neutralising antibody titres on day 28", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 59}], "Observation": [{"term": "significantly greater", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 86}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "4 \u03bcg days 0 and 14", "has_relation": "N/A"}], "Observation": "significantly greater", "Outcome": "vaccine-elicited neutralising antibody titres on day 28", "Count": ""}]}, {"Section": "INTERPRETATION", "Text": "The inactivated SARS-CoV-2 vaccine , BBIBP-CorV , is safe and well tolerated at all tested doses in two age groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated SARS-CoV-2 vaccine , BBIBP-CorV", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 47, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 57}, {"term": "well tolerated", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 76}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Humoral responses against SARS-CoV-2 were induced in all vaccine recipients on day 42 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "all vaccine", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 64, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 4, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "Humoral responses against SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 36}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Two-dose immunisation with 4 \u03bcg vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres than the single 8 \u03bcg dose or 4 \u03bcg dose on days 0 and 14 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Two-dose immunisation with 4 \u03bcg vaccine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 39, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 32, "end": 39}], "has_procedure": [{"text": "immunisation", "maps_to": "C0020971:immunisation", "start": 9, "end": 21, "has_dosage": ["two dose"]}], "has_relation": "combined_with (C0020971<->C0042210)"}, {"term": "single 8 \u03bcg dose or 4 \u03bcg dose", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 157, "has_relation": "N/A"}], "Outcome": [{"term": "neutralising antibody titres", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 118}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 89}], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "National Program on Key Research Project of China , National Mega projects of China for Major Infectious Diseases , National Mega Projects of China for New Drug Creation , and Beijing Science and Technology Plan .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}